ALDA Pharmaceuticals Corp.
TSX VENTURE : APH
OTC Bulletin Board : APCSF

ALDA Pharmaceuticals Corp.

May 11, 2009 13:47 ET

ALDA Expands Marketing Efforts and Appoints Account Manager

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 11, 2009) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) ("the Company" or "ALDA") has named Ms. Diane Mann to the new position of Account Manager.

Ms. Mann received her B.Sc. in General Science, with emphasis on Biochemistry and Microbiology, from the University of Manitoba in 1989. With nearly 20 years of experience in the brokerage, investment, communications, direct sales and investor relations businesses, Diane brings a solid understanding of sales, marketing and communications.

Dr. Terrance Owen, President & CEO, states, "We are excited to have Diane join our team as we start implementing our marketing program. We have many untapped markets for our products and new ideas are coming to us all the time. We have done test marketing in selected pharmacies and the results have been very encouraging. We now intend to pursue sales in areas we have not previously served, such as banks, casinos, offices, sports teams, restaurants, travel agents and many other avenues. Now that we have more products for personal use and commercial use, it is time to seek new outlets for our products and provide additional support to all of our distributors."

The products available at this time include:

- T36® Disinfectant

- T36® Disinfectant Wipes

- T36® Antiseptic Hand Sanitizer Gel

- T36® Antiseptic Hand Sanitizer Wipes

- T36® Disinfectant Cleaner CONCENTRATE

Additional products that are in progress include T36® Antiseptic Hand Sanitizer Liquid and T36 Disinfex™ Disinfectant Cleaner.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTC BB under the symbol APCSF.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Contact Information

  • Retail Sales
    Eastern Esthetics (ON, QU, NB, NS, PE, NL)
    902-450-2161
    or
    Retail Sales
    LCN Canada - West (MB, SK, AB, BC, NW, YK)
    780-462-2580
    or
    ALDA Pharmaceuticals Corp.
    Peter Chen
    Distribution & Sales Contact
    604-521-8300 Ext. 3
    604-521-8322 (FAX)
    peter_chen@aldacorp.com
    or
    ALDA Pharmaceuticals Corp.
    Scott Young
    Investor Relations Contact
    604-288-7222
    syoung@freeformcom.com
    www.aldacorp.com